- HealthTech
- Monday, 06 Jan 2020
Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the opening of a clinical study to evaluate the safety and preliminary clinical efficacy of MRx0518 in combination with preoperative radiotherapy in 15 patients with resectable pancreatic cancer.
The study is being conducted at The University of Texas MD Anderson Cancer Center and is the second opened as part of a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings. Cullen M. Taniguchi, M.D., Ph.D., Assistant Professor of Radiation Oncology at MD Anderson, is the principal investigator for the study.
Subjects will be dosed daily with MRx0518 for one week prior to and throughout radiotherapy, up until 24 hours prior to surgical resection. In addition to the primary endpoint of safety and tolerability, the study will evaluate the preliminary clinical efficacy of the combination including assessment of major pathologic response, Progression Free Survival (PFS) and Overall Survival (OS). Additional secondary and exploratory endpoints will assess changes in tumour infiltrating lymphocytes (TILs) and the gut microbiome.
Alex Stevenson, 4D's Chief Scientific Officer, commented:
"Pancreatic cancer carries a poor prognosis and remains an area of significant unmet need. Encouraged by promising early signals in our other clinical studies, we believe MRx0518 has the potential to offer new treatment options and dramatically improve outcomes for patients with pancreatic cancer. This third study demonstrates 4D's ongoing commitment to oncology."
4D recently announced clinical observations from its ongoing open-label study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in patients with solid tumours that have progressed on prior checkpoint inhibitor therapy with no known alternative treatment options. The combination is well tolerated with no drug-related adverse events, and currently has induced partial responses in two of six evaluable patients and stable disease in a third patient.
Related Industry Updates
Cosmetic Surgery Market Estimated To Flourish By 2027 Competitors like- Johnson & Johnson Services, Inc., Alma Lasers, Merz Pharma, Allergan, Cynosure, Inc., Sientra, Inc., Galderma S.A.,
Mar 31, 2021
Cancer Registry Software Market 2021 is Thriving Worldwide with Top Vendors Onco, Inc, C/Net Solutions, Elekta AB, Rocky Mountain Cancer Data Systems, Electronic Registry Systems, Inc
Mar 11, 2021
Big Data In Healthcare Market 2021- Key Strategy, Revenue, Opportunity, Business Segment Overview and Key Trends -2027| Cerner Corporation, Cognizant, Dell, GE Healthcare, Mckesson, Optum, Philips & More
Apr 09, 2021
All Ceramic Bridge Market Size Sees Promising Growth To Cross Highest Revenue By 2020
Dec 09, 2020
North America Patient Registry Software Market 2020 Manufacturers Profiles with Industry Size, Trends and Forecast by 2027 |
Aug 13, 2020
Explore why South Africa Anti-Infective Market is Thriving Worldwide 2020-2027 with an increase in Revenue of $2572.5Mn
Sep 23, 2020
Europe Healthcare Contract Research Organizations (CRO) Services Market Size, Share, Demand, Analysis and Forecast To 2027 | ICON plc,IQVIA INC,Laboratory Corporation of America Holdings (Covance),PRA Health Sciences,Syneos Health
Nov 25, 2020